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Abstract
We present the clinical case of a 74-year-old woman with an urachal tumor diagnosed in 
2004. The patient underwent a partial cystectomy of the dome with remotion of the 
urachal remnant and the umbilicus. She had been clinical well until 2011 when she had a 
kidney metastasis from the urachal tumor.
Urachal tumors are very rare, comprising 0.17-0.34% of all bladder cancers. The most 
common sites of distant metastases are: lung, lymph nodes, bone, intestine, brain, liver, 
peritoneum, skin and spine. We describe an extremely rare case of a renal metastasis 
from an urachal cancer, seven years after the initial diagnosis.
Usually, patients with localized disease have a good prognosis when treated with surgery. 
The prognosis gets worse for patients with metastases or local recurrence because a 
standard chemotherapy regimen does not exist.
© 2015 Associação Portuguesa de Urologia.Published by Elsevier España, S.L.U. This is 
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Adenocarcinoma do úraco – metástase atípica de um tumor raro
Resumo
Apresentamos o caso clinico de uma doente com 74 anos diagnosticada com tumor do 
úraco em 2004. A doente foi submetida a cistectomia parcial da cúpula vesical com exci-
são do úraco e do umbigo. Esteve clinicamente bem até 2011 quando lhe foi diagnostica-
da uma metástase renal do tumor do úraco.
Os tumores do úraco são muito raros, compreendendo 0,17-0,34% de todos os tumores 
da bexiga. Os locais mais comuns de metastização à distância são: pulmão, gânglios 
linfáticos, osso, intestino, fígado, peritoneu, pele e coluna. Descrevemos um caso extre-
mamente raro de uma metástase renal de um adenocarcinoma do úraco sete anos após 
o diagnóstico inicial.
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Introduction
Urachal adenocarcinomas are very rare tumors, usually 
diagnosed at an advanced stage because the lack of symp-
toms. We present a rare case of a renal metastasis develo-
SHGVHYHQ\HDUVDIWHUWKHÀUVWWUHDWPHQW
Case report
We present the case of a 74-year-old woman that was sent 
to the urologist in 2003 to investigate gross hematuria. 
She did a computed tomography (CT) scan that showed a 
proliferative mass of the anterior bladder wall. The cys-
WRVFRSLF HYDOXDWLRQ FRQÀUPHG D OHVLRQ DW WKH EODGGHU
dome. The lesion was ressected and the histology revealed 
LQÀOWUDWLRQRIWKHEODGGHUPXFRVDE\PXFLQRXVDGHQRFDU-
cinoma.
Gynecology and General Surgery excluded secondary 
adenocarcinoma of the bladder.
A partial cystectomy of the dome was performed with 
remotion of the urachal remnant and the umbilicus. The 
KLVWRORJ\UHYHDOHGLQÀOWUDWLRQRIWKHEODGGHUPXFRVDE\PX-
cinous urachal adenocarcinoma (Fig. 1).
The follow-up was maintained and the patient had been 
clinically well until November 2011, when the CT scan of 
the abdomen and pelvis revealed a renal mass involving the 
lower pole of the left kidney. This mass had 75×41×54 mm 
and its appearance was suspicious for a proliferative lesion. 
There was no evidence of lymphadenopathies.
The patient underwent a laparoscopic radical nephrec-
tomy of the left kidney on January 2012. 
7KHKLVWRORJ\VKRZHGLQÀOWUDWLRQRIWKHUHQDOSDUHQFK\-
ma from the Gerota fascia to the calyces by mucinous ade-
nocarcinoma (Fig. 2). Imunohistochemical staining showed 
that cells were positive to CK20 but negative to CK7. Neural 
invasion was present and the margins were positive. The 
KLVWRORJLFH[DPFRQFOXGHGVHFRQGDU\LQÀOWUDWLRQRIWKHNLG-
ney by mucinous adenocarcinoma similar to the analyses 
performed in 2003.
The gynecologic exam and the colonoscopy did not reveal 
alterations. It was concluded that the kidney mass was a 
metastasis from the urachal tumor.
On May 2012, the patient had an episode of intestinal 
subocclusion and was admitted in the General Surgery’s De-
partment. During this period she underwent a virtual colo-
noscopy that did not reveal polipoid images. The CT scan of 
the thorax, abdomen and pelvis showed a latero-aortic lym-
ph node and a heterogeneous lesion in the renal fossa su-
gestive of local relapse. 
The serum levels of carcinoembryonic antigen (CEA) 
were elevated.
With evidence of disease progression the patient was 
sent to the Oncologist. She began salvage chemotherapy 
with Gemcitabine, once a week.
A CT scan performed on February 2013 showed volume 
reduction of the residual mass and of the latero-aortic lym-
ph node. However it was also documented progression of 
WKHGLVHDVHZLWKLGHQWLÀFDWLRQRIDOXPEDUYHUWHEUDOVLQNLQJ
The patient died on March 2013.
Habitualmente, os doentes com doença localizada apresentam um bom prognóstico 
quando tratados com cirurgia. O diagnóstico é pior para doentes com metástases ou 
recorrência local uma vez que ainda não existe um regime de quimioterapia estabele-
cido.
© 2015 Associação Portuguesa de Urologia. Publicado por Elsevier España, S.L.U. Este 
é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Figure 1 ,QÀOWUDWLRQRIWKHEODGGHUPXFRVDE\PXFLQRXVDGH-
nocarcinoma. (Hematoxylin-eosin, 40×).
Figure 2 ,QÀOWUDWLRQ RI WKH UHQDO SDUHQFK\PD E\ PXFLQRXV
adenocarcinoma. (Hematoxylin-eosin, 40×).
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Discussion
Adenocarcinoma of the bladder comprises less than 2% of 
all bladder carcinomas. They could arise from the bladder 
proper or from the urachus, or could be an extension of 
adenocarcinoma from adjacent organs or metastases from a 
distant organ.1
The histological differentiation between vesical, urachal 
DQG PHWDVWDWLF DGHQRFDUFLQRPD LV GLIÀFXOW DQG UHTXLUHV
FRUUHODWLRQRIFOLQLFDODQGSDWKRORJLFDOÀQGLQJV1,2
The immunostaining with CK7 and CK20 is used in surgical 
pathology to help determine the origin of epithelial neoplas-
PV+RZHYHUE\LWVHOILWGRHVQRWSURYLGHVXIÀFLHQWVSHFLÀFL-
ty to allow accurate distinction between secondary colorec-
tal adenocarcinomas and primary bladder adenocarcinomas.3
In order to diagnose an urachal cancer some criteria have 
WR EH IXOÀOOHG 7DEOH  6RPH LQYHVWLJDWRUV FRQVLGHU DQ\
patient presenting with an enteric-type adenocarcinoma of 
the bladder, at the bladder dome or elsewhere in the midli-
ne as having an urachal tumor until proven otherwise.4
Urachal tumors are very rare neoplasms that represent 
0.01% of all cancers5 and 0.17-0.34% of all bladder cancers.6
The majority of cases are described in men, with many 
reports indicating a median age at diagnosis of approxima-
tely 50-60 years.5,7,8
A systematic review of the literature reveals a 5-year sur-
vival rate of less than 25%,5,6 although some studies realized 
in Mayo Clinic revealed a 5-year survival rate of 43-49%.7,8
Patients with this kind of tumor most commonly present 
with hematuria.6-8 Another symptoms described by different 
authors are: mucinuria, palpable mass in the lower abdo-
men, bacteriuria, pain, disuria and umbilical discharge.4,6,7
Owing to lack of early symptoms, the cancer usually pre-
sents at an advanced stage.4,5,9,10
The cystocopy usually shows a mass at the dome of the 
bladder or anterior wall which could be described in appea-
rance as a polypoid or ulcerated lesion.6,7
Like other enteric-type adenocarcinomas, urachal tu-
mors may have detectable serum levels of CEA, CA125 and 
cancer antigen 19-9. These serum markers could be helpful 
in evaluating response to systemic chemotherapy.4,10
The gold standard of treatment is the surgery that inclu-
des an en bloc resection of the urachal ligament and umbi-
licus with a complete or partial cystectomy.4,6,10 Sampling 
lymph nodes allows a better staging of the disease.7
Some authors describe as risk factors associated with re-
currence after surgery: positive margins, lymph node or 
other metastases at the time of surgery, tumor grade and 
failure to resect the umbilicus.4,5,8
Local recurrence after surgery include: pelvic lymph no-
des, peritoneum and omentum. The most common sites of 
distant metastases are: lung, lymph nodes, bone, intestine, 
brain, liver, peritoneal carcinomatosis, skin and spine.4,7,8 
The rare distant metastases are: scalp, pleural effusion, 
adrenal, abdominal wall, pancreas and orbit.4
Surgical resection of local tumor recurrences can be 
curative, but the role of radiation therapy and chemothera-
py are unclear.8
There is no standard chemotherapy regimen and the 
choice of regimens has been based on case reports and sin-
gle institution experiences.10
The standard chemotherapy for this type of cancer shou-
ld include a taxane or a regimen used to treat gastrointes-
tinal malignances as opposed to standard transicional cell 
FDUFLQRPDUHJLPHQVZKLFKKDYHQRWVKRZQPXFKHIÀFDF\10 
The clinical trial with *HPFLWDELQHÁXRURXUDFLOOHXFRYR-
rin+cisplatin (Gem-FLP) is showing promise and may provide 
a chemotherapy standard.4,10
Usually, patients with localized disease have a good 
prognosis when treated with surgery. The prognosis gets 
worse for patients with metastases or local recurrence as 
we show with this case. 
We described a renal metastasis from urachal cancer. 
This clinical case shows that positive margins after surgery 
may represent a risk factor to recurrence. Given the rarity 
RIXUDFKDOFDQFHUDOOQHZÀQGLQJVDUHLPSRUWDQWWRLPSURYH
the knowledge in this area. The creation of randomized 
follow-up studies with collaboration of different institu-
tions is necessary to investigate the role of adjuvant and 
salvage therapies and establish a standard regimen.
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Table 1 MD Anderson Cancer Centre Criteria for the diag-
nosis of urachal cancer.
Location in the bladder dome or elsewhere  
in the midline of the bladder
Sharp demarcation between tumor and normal  
surface epithelium
Supportive criteria
Enteric-type histology
Absence of urothelial dysplasia
Absence of cystitis cystic or cystitis glandularis  
transitioning to the tumor
Absence of primary adenocarcinoma of another organ
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